Axel Hoos
Research Subjects
Axel Hoos has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
C R Antonescu
2 shared publicationsJ M Woodruff
2 shared publications- Jonathan J. Lewis
Departments of Surgery, Biostatistics, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
2 shared publications M F Brennan
2 shared publicationsC Cordon-Cardo
1 shared publicationCarlos Cordon-Cardo
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York
1 shared publication
Latest Publications
- 1 January 2004
- Vol. 116, 109
Autologous heat shock protein-peptide complexes for vaccination against cancer: from bench to bedside.
Random mutations in cancer cells generate unique antigens in each patient's tumour, warranting a personalized treatment approach. Autologous heat shock protein-peptide complexes (HSPPCs) produced from a patient's cancer tissue provide such a personalized approach without the need to identify the unique antigens contained in the individual vaccine. HSPPCs elicit adaptive and innate immune responses and have been tested in a variety of animal models and different human cancers. Currently, there are more than 150 medical centres worldwide enrolling cancer patients in randomized, controlled Phase III clinical trials testing autologous HSPPCs vaccines. This review summarizes the key steps involved in the translation of HSPPCs--from basic science to advanced clinical investigation.
- 1 January 2004
- Vol. 116, 109
Autologous heat shock protein-peptide complexes for vaccination against cancer: from bench to bedside.
Random mutations in cancer cells generate unique antigens in each patient's tumour, warranting a personalized treatment approach. Autologous heat shock protein-peptide complexes (HSPPCs) produced from a patient's cancer tissue provide such a personalized approach without the need to identify the unique antigens contained in the individual vaccine. HSPPCs elicit adaptive and innate immune responses and have been tested in a variety of animal models and different human cancers. Currently, there are more than 150 medical centres worldwide enrolling cancer patients in randomized, controlled Phase III clinical trials testing autologous HSPPCs vaccines. This review summarizes the key steps involved in the translation of HSPPCs--from basic science to advanced clinical investigation.
- 1 June 2003
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 2 (3) , 369-379
Vaccination with heat shock protein–peptide complexes: from basic science to clinical applications
There are currently over 150 medical centers worldwide enrolling patients in randomized, controlled Phase III clinical trials testing autologous cancer-derived heat-shock protein (HSP)-peptide complexes for the treatment of renal cell carcinoma and melanoma. In addition, autologous HSP-peptide complexes have been or are being tested in Phase I and II trials of chronic myelogenous leukemia, lymphoma and pancreatic, gastric and colorectal cancers. The door has more recently opened to clinical testing of off-the-shelf HSP-based treatments for infectious diseases. This review recounts the long history of basic research on HSPs in immune response. A keen understanding of how these ancient molecules orchestrate the immune response to cancer and infections has been gained, providing a clear rationale for translating this knowledge into clinical medicine.
- 1 June 2003
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 2 (3) , 369-379
Vaccination with heat shock protein–peptide complexes: from basic science to clinical applications
There are currently over 150 medical centers worldwide enrolling patients in randomized, controlled Phase III clinical trials testing autologous cancer-derived heat-shock protein (HSP)-peptide complexes for the treatment of renal cell carcinoma and melanoma. In addition, autologous HSP-peptide complexes have been or are being tested in Phase I and II trials of chronic myelogenous leukemia, lymphoma and pancreatic, gastric and colorectal cancers. The door has more recently opened to clinical testing of off-the-shelf HSP-based treatments for infectious diseases. This review recounts the long history of basic research on HSPs in immune response. A keen understanding of how these ancient molecules orchestrate the immune response to cancer and infections has been gained, providing a clear rationale for translating this knowledge into clinical medicine.
- Open Access
- 1 October 2001
- Published by Elsevier in Laboratory Investigation
- Vol. 81 (10) , 1331-1338
Tissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations
- 1 October 2001
- Published by Elsevier in Laboratory Investigation
- Vol. 81 (10) , 1331-1338
Open AccessTissue Microarray Profiling of Cancer Specimens and Cell Lines: Opportunities and Limitations
- 1 April 2001
- Vol. 61 (7) , 3171-5
Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors.
Desmoid tumors and fibrosarcomas (FS) are part of a wide spectrum of disordered fibroblastic growth that display striking clinical and phenotypic differences. This study was designed to characterize molecular abnormalities that are associated with these differences and to determine their clinical relevance. A cohort of 24 desmoid tumors and 25 low-grade (LG) and 14 high-grade (HG) FS that were clinically and pathologically well characterized was analyzed for alterations in expression of Ki-67, Bcl-2, retinoblastoma gene product (pRB), and p53 by immunohistochemistry. LG-FS and HG-FS showed abnormal expression of Ki-67 (32 versus 86%), Bcl-2 (48 versus 57%), and pRB (56 versus 93%). In contrast, desmoid tumors showed a normal phenotype with these markers. p53 overexpression was identified in 20% of LG-FS and in 29% of HG-FS cases but only in 4% of desmoid tumors. There was an increasing trend in the proportion of abnormal expression of Ki-67, Bcl-2, pRB, and p53 with the increase of tumor aggressiveness from desmoid tumors to LG-FS to HG-FS. The molecular differences between tumor entities were highly statistically significant (P < 0.01). Significant associations between abnormal expression of pRB and recurrence-free survival of LG-FS patients (P = 0.05) and between Ki-67 overexpression and recurrence-free survival for tumors of >5 cm were observed (P = 0.02). The demonstrated differences of molecular alterations in HG-FS, LG-FS, and desmoids appear to be related to biological aggressiveness of such tumors, and they might be useful to differentiate between histologically similar cases of desmoid tumors and LG-FS. pRB and Ki-67 status may be useful to predict recurrence in certain subsets of patients.
- 1 April 2001
- Vol. 61 (7) , 3171-5
Characterization of molecular abnormalities in human fibroblastic neoplasms: a model for genotype-phenotype association in soft tissue tumors.
Desmoid tumors and fibrosarcomas (FS) are part of a wide spectrum of disordered fibroblastic growth that display striking clinical and phenotypic differences. This study was designed to characterize molecular abnormalities that are associated with these differences and to determine their clinical relevance. A cohort of 24 desmoid tumors and 25 low-grade (LG) and 14 high-grade (HG) FS that were clinically and pathologically well characterized was analyzed for alterations in expression of Ki-67, Bcl-2, retinoblastoma gene product (pRB), and p53 by immunohistochemistry. LG-FS and HG-FS showed abnormal expression of Ki-67 (32 versus 86%), Bcl-2 (48 versus 57%), and pRB (56 versus 93%). In contrast, desmoid tumors showed a normal phenotype with these markers. p53 overexpression was identified in 20% of LG-FS and in 29% of HG-FS cases but only in 4% of desmoid tumors. There was an increasing trend in the proportion of abnormal expression of Ki-67, Bcl-2, pRB, and p53 with the increase of tumor aggressiveness from desmoid tumors to LG-FS to HG-FS. The molecular differences between tumor entities were highly statistically significant (P < 0.01). Significant associations between abnormal expression of pRB and recurrence-free survival of LG-FS patients (P = 0.05) and between Ki-67 overexpression and recurrence-free survival for tumors of >5 cm were observed (P = 0.02). The demonstrated differences of molecular alterations in HG-FS, LG-FS, and desmoids appear to be related to biological aggressiveness of such tumors, and they might be useful to differentiate between histologically similar cases of desmoid tumors and LG-FS. pRB and Ki-67 status may be useful to predict recurrence in certain subsets of patients.
- 15 February 2001
- Vol. 91 (4) , 794-803
Clinicopathologic analysis of patients with adult rhabdomyosarcoma.
Rhabdomyosarcoma (RMS) in adults (age > or = 16 years) is rare, accounting for less than 3% of adult soft tissue sarcomas. There is little information describing the disease biology or clinicopathologic factors that influence survival in adults with RMS. The objective of this study was to define the factors in patients with adult RMS that predict outcome, disease progression, and survival. Eighty-four adult patients with a pathologic diagnosis of RMS that was confirmed by immunohistochemistry were identified by a prospective inpatient data base during the period 1982--1999 and were analyzed for disease specific survival and metastasis free survival using the Kaplan-Meier actuarial method. Statistical significance was evaluated using the log-rank test for univariate influence and a Cox regression model for multivariate influence. The median disease specific survival was 22 months. Patient age, extent of disease, tumor size at the time of diagnosis, and margin status after resection were significant predictors of disease specific survival. Patients who underwent a complete resection had a significantly longer median survival (105 months) compared with any other subgroup of patients. The histologic subtype did not predict patient survival but did vary with patient age. Most notably, the proportion of the pleomorphic subtype increased with advancing age, accounting for 42% of RMS in patients over the age of 40 years. The most important predictors of outcome in patients with adult RMS are patient age, tumor size, extent of disease, and margin status after resection. In contrast to patients with pediatric RMS, no association was noted between survival and histologic subtype in this group of patients with adult RMS. All histologic subtypes of RMS are aggressive malignancies with poor disease specific survival despite aggressive multimodality management.
- 15 February 2001
- Vol. 91 (4) , 794-803
Clinicopathologic analysis of patients with adult rhabdomyosarcoma.
Rhabdomyosarcoma (RMS) in adults (age > or = 16 years) is rare, accounting for less than 3% of adult soft tissue sarcomas. There is little information describing the disease biology or clinicopathologic factors that influence survival in adults with RMS. The objective of this study was to define the factors in patients with adult RMS that predict outcome, disease progression, and survival. Eighty-four adult patients with a pathologic diagnosis of RMS that was confirmed by immunohistochemistry were identified by a prospective inpatient data base during the period 1982--1999 and were analyzed for disease specific survival and metastasis free survival using the Kaplan-Meier actuarial method. Statistical significance was evaluated using the log-rank test for univariate influence and a Cox regression model for multivariate influence. The median disease specific survival was 22 months. Patient age, extent of disease, tumor size at the time of diagnosis, and margin status after resection were significant predictors of disease specific survival. Patients who underwent a complete resection had a significantly longer median survival (105 months) compared with any other subgroup of patients. The histologic subtype did not predict patient survival but did vary with patient age. Most notably, the proportion of the pleomorphic subtype increased with advancing age, accounting for 42% of RMS in patients over the age of 40 years. The most important predictors of outcome in patients with adult RMS are patient age, tumor size, extent of disease, and margin status after resection. In contrast to patients with pediatric RMS, no association was noted between survival and histologic subtype in this group of patients with adult RMS. All histologic subtypes of RMS are aggressive malignancies with poor disease specific survival despite aggressive multimodality management.